Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

A haplotype variation affecting the mitochondrial transportation of hMYH protein could be a risk factor for colorectal cancer in Chinese

Authors: Huimei Chen, Lizhi Xu, Qiufeng Qi, Yanweng Yao, Ming Zhu, Yaping Wang

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

The human MutY homolog (hMYH), a DNA glycolsylase involved in the excision repair of oxidative DNA damage, is currently studied in colorectal cancer (CRC). We previously demonstrated a haplotype variant c.53C>T/c.74G>A of hMYH (T/A) increasing the risk for gastric cancer in Chinese. However, most investigations on correlation between hMYH and CRC are conducted in Western countries and the underlying mechanism has been poorly understood.

Methods

To determine whether the haplotype T/A variant of hMYH was related to colorectal carcinogenesis, we performed a case-control study in 138 colorectal cancer (CRC) patients and 343 healthy controls in a Chinese population. Furthermore, the C/G for wild-type, C/A or T/G for single base variant and T/A for haplotype variant hMYH cDNAs with a flag epitope tag were cloned into pcDNA3.1+ vector and transfected into cos-7 cell line. Their subcellular localizations were determined by immunofluorescence assay.

Results

It was found that the frequency of haplotype variant allele was statistically higher in CRC patients than that in controls (P = 0.02, odds ratio = 5.06, 95% confidence interval = 1.26 – 20.4). Similarly, significant difference of heterozygote frequency was indicated between the two groups (P = 0.019), while no homozygote was found. In addition, immunofluorescence analysis showed that hMYH protein with haplotype T/A variation presented in both nucleus and mitochondria, in contrast to the wild-type protein only converging in mitochondria. However, neither of the single missense mutations alone changed the protein subcelluar localization.

Conclusion

Although preliminarily, these results suggest that: the haplotype variant allele of hMYH leads to a missense protein, which partly affects the protein mitochondrial transportation and results as nuclear localization. This observation might be responsible for the increased susceptibility to cancers, including CRC, in Chinese.
Appendix
Available only for authorised users
Literature
1.
Hitomi K, Iwai S, Tainer JA: The intricate structural chemistry of base excision repair machinery: implications for DNA damage recognition, removal, and repair. DNA Repair (Amst). 2007, 6 (4): 410-428.CrossRef
2.
Kino K, Sugiyama H: UVR-induced G-C to C-G transversions from oxidative DNA damage. Mutat Res. 2005, 571 (1–2): 33-42.CrossRefPubMed
3.
4.
McGoldrick JP, Yeh YC, Solomon M, Essigmann JM, Lu AL: Characterization of a mammalian homolog of the Escherichia coli MutY mismatch repair protein. Mol Cell Biol. 1995, 15 (2): 989-996.CrossRefPubMedPubMedCentral
5.
Michaels ML, Cruz C, Grollman AP, Miller JH: Evidence that MutY and MutM combine to prevent mutations by an oxidatively damaged form of guanine in DNA. Proc Natl Acad Sci USA. 1992, 89 (15): 7022-7025.CrossRefPubMedPubMedCentral
6.
Lu AL, Bai H, Shi G, Chang DY: MutY and MutY homologs (MYH) in genome maintenance. Front Biosci. 2006, 11: 3062-3080.CrossRefPubMed
7.
Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, Hodges AK, Davies DR, David SS, Sampson JR, et al: Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors. Nat Genet. 2002, 30 (2): 227-232.CrossRefPubMed
8.
Sampson JR, Dolwani S, Jones S, Eccles D, Ellis A, Evans DG, Frayling I, Jordan S, Maher ER, Mak T, et al: Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet. 2003, 362 (9377): 39-41.CrossRefPubMed
9.
Zhang Y, Liu X, Fan Y, Ding J, Xu A, Zhou X, Hu X, Zhu M, Zhang X, Li S, et al: Germline mutations and polymorphic variants in MMR, E-cadherin and MYH genes associated with familial gastric cancer in Jiangsu of China. Int J Cancer. 2006, 119 (11): 2592-2596.CrossRefPubMed
10.
Shinmura K, Yamaguchi S, Saitoh T, Kohno T, Yokota J: Somatic mutations and single nucleotide polymorphisms of base excision repair genes involved in the repair of 8-hydroxyguanine in damaged DNA. Cancer Lett. 2001, 166 (1): 65-69.CrossRefPubMed
11.
Kim DW, Kim IJ, Kang HC, Jang SG, Kim K, Yoon HJ, Ahn SA, Han SY, Hong SH, Hwang JA, et al: Germline mutations of the MYH gene in Korean patients with multiple colorectal adenomas. Int J Colorectal Dis. 2007, 22 (10): 1173-1178.CrossRefPubMed
12.
Halford SE, Rowan AJ, Lipton L, Sieber OM, Pack K, Thomas HJ, Hodgson SV, Bodmer WF, Tomlinson IP: Germline mutations but not somatic changes at the MYH locus contribute to the pathogenesis of unselected colorectal cancers. Am J Pathol. 2003, 162 (5): 1545-1548.CrossRefPubMedPubMedCentral
13.
14.
Li S, Nie Z, Li N, Li J, Zhang P, Yang Z, Mu S, Du Y, Hu J, Yuan S, et al: Colorectal cancer screening for the natural population of Beijing with sequential fecal occult blood test: a multicenter study. Chin Med J (Engl). 2003, 116 (2): 200-202.
15.
Ma H, Lee HM, Englander EW: N-terminus of the rat adenine glycosylase MYH affects excision rates and processing of MYH-generated abasic sites. Nucleic Acids Res. 2004, 32 (14): 4332-4339.CrossRefPubMedPubMedCentral
16.
Ohtsubo T, Nishioka K, Imaiso Y, Iwai S, Shimokawa H, Oda H, Fujiwara T, Nakabeppu Y: Identification of human MutY homolog (hMYH) as a repair enzyme for 2-hydroxyadenine in DNA and detection of multiple forms of hMYH located in nuclei and mitochondria. Nucleic Acids Res. 2000, 28 (6): 1355-1364.CrossRefPubMedPubMedCentral
17.
Takao M, Aburatani H, Kobayashi K, Yasui A: Mitochondrial targeting of human DNA glycosylases for repair of oxidative DNA damage. Nucleic Acids Res. 1998, 26 (12): 2917-2922.CrossRefPubMedPubMedCentral
18.
Wang AL, Lukas TJ, Yuan M, Neufeld AH: Increased mitochondrial DNA damage and down-regulation of DNA repair enzymes in aged rodent retinal pigment epithelium and choroid. Mol Vis. 2008, 14: 644-651.PubMedPubMedCentral
19.
Greaves LC, Taylor RW: Mitochondrial DNA mutations in human disease. IUBMB Life. 2006, 58 (3): 143-151.CrossRefPubMed
20.
Green K, Brand MD, Murphy MP: Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes. 2004, 53 (Suppl 1): S110-118.CrossRefPubMed
21.
Lievre A, Chapusot C, Bouvier AM, Zinzindohoue F, Piard F, Faivre J, Laurent-Puig P: Mitochondrial DNA mutations in colorectal cancer a prognostic and a predictive factor of response to adjuvant chemotherapy. J Clin Oncol. 2004, 22 (14): 863s-863s.
22.
Reddy PH: Mitochondrial oxidative damage in aging and Alzheimer's disease: Implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotechnol. 2006
23.
Sobin LHWC, editors: UICC: TNM Classification of Malignant Tumors. 2002, New York: Wiley-Liss, 6
24.
Gross E, Arnold N, Goette J, Schwarz-Boeger U, Kiechle M: A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet. 1999, 105 (1–2): 72-78.CrossRefPubMed
25.
Yamaguchi S, Shinmura K, Saitoh T, Takenoshita S, Kuwano H, Yokota J: A single nucleotide polymorphism at the splice donor site of the human MYH base excision repair genes results in reduced translation efficiency of its transcripts. Genes Cells. 2002, 7 (5): 461-474.CrossRefPubMed
26.
Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR: Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989, 77 (1): 51-59.CrossRefPubMed
27.
Ichinoe A, Behmanesh M, Tominaga Y, Ushijima Y, Hirano S, Sakai Y, Tsuchimoto D, Sakumi K, Wake N, Nakabeppu Y: Identification and characterization of two forms of mouse MUTYH proteins encoded by alternatively spliced transcripts. Nucleic Acids Res. 2004, 32 (2): 477-487.CrossRefPubMedPubMedCentral
28.
Evans MD, Dizdaroglu M, Cooke MS: Oxidative DNA damage and disease: induction, repair and significance. Mutat Res. 2004, 567 (1): 1-61.CrossRefPubMed
29.
30.
31.
Li M, Li JY, Zhao AL, Gu J: Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas. Oncology. 2007, 73 (1–2): 52-57.CrossRefPubMed
32.
Shin Y, Kim IJ, Kang HC, Park JH, Park HW, Jang SG, Lee MR, Jeong SY, Chang HJ, Ku JL, et al: A functional polymorphism (-347 G -> GA) in the E-cadherin gene is associated with colorectal cancer. Carcinogenesis. 2004, 25 (11): 2173-2176.CrossRefPubMed
33.
Sutton MD, Walker GC: Managing DNA polymerases: coordinating DNA replication, DNA repair, and DNA recombination. Proc Natl Acad Sci USA. 2001, 98 (15): 8342-8349.CrossRefPubMedPubMedCentral
34.
Nakabeppu Y: Regulation of intracellular localization of human MTH1, OGG1, and MYH proteins for repair of oxidative DNA damage. Prog Nucleic Acid Res Mol Biol. 2001, 68: 75-94.CrossRefPubMed
35.
Yeh YC, Chang DY, Masin J, Lu AL: Two nicking enzyme systems specific for mismatch-containing DNA in nuclear extracts from human cells. J Biol Chem. 1991, 266 (10): 6480-6484.PubMed
36.
Tsai-Wu JJ, Su HT, Wu YL, Hsu SM, Wu CH: Nuclear localization of the human mutY homologue hMYH. J Cell Biochem. 2000, 77 (4): 666-677.CrossRefPubMed
37.
Takao M, Zhang QM, Yonei S, Yasui A: Differential subcellular localization of human MutY homolog (hMYH) and the functional activity of adenine:8-oxoguanine DNA glycosylase. Nucleic Acids Res. 1999, 27 (18): 3638-3644.CrossRefPubMedPubMedCentral
38.
Parker A, Gu Y, Lu AL: Purification and characterization of a mammalian homolog of Escherichia coli MutY mismatch repair protein from calf liver mitochondria. Nucleic Acids Res. 2000, 28 (17): 3206-3215.CrossRefPubMedPubMedCentral
39.
Ott M, Gogvadze V, Orrenius S, Zhivotovsky B: Mitochondria, oxidative stress and cell death. Apoptosis. 2007, 12 (5): 913-922.CrossRefPubMed
40.
Barja G, Herrero A: Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heart and brain of mammals. FASEB J. 2000, 14 (2): 312-318.PubMed
41.
Croteau DL, Stierum RH, Bohr VA: Mitochondrial DNA repair pathways. Mutat Res. 1999, 434 (3): 137-148.CrossRefPubMed
42.
Bohr VA: Repair of oxidative DNA damage in nuclear and mitochondrial DNA, and some changes with aging in mammalian cells. Free Radic Biol Med. 2002, 32 (9): 804-812.CrossRefPubMed
Metadata
Title
A haplotype variation affecting the mitochondrial transportation of hMYH protein could be a risk factor for colorectal cancer in Chinese
Authors
Huimei Chen
Lizhi Xu
Qiufeng Qi
Yanweng Yao
Ming Zhu
Yaping Wang
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-269

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures

Research article

Dissemination of periodic mammography and patterns of use, by birth cohort, in Catalonia (Spain)

Research article

The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis

Research article

A family history of breast cancer will not predict female early onset breast cancer in a population-based setting

Research article

Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples

Research article

Cancer survival among children of Turkish descent in Germany 1980–2005: a registry-based analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits